Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

365 ARTÍCULOS , VIENDO DEL 136 AL 150

Transdermal rivastigmine for Alzheimer's disease: skin deep or scratching the surface?

Larner AJ.

Int J Clin Pract. 2010 Apr;64(5):534-6. doi: 10.1111/j.1742-1241.2009.02305.x.

An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease

Roses AD.

Arch Neurol. 2010 May;67(5):536-41. doi: 10.1001/archneurol.2010.88.

Protective role of methylene blue in Alzheimer's disease via mitochondria and cytochrome c oxidase

Atamna H, Kumar R.

J Alzheimers Dis. 2010;20 Suppl 2:S439-52. doi: 10.3233/JAD-2010-100414.

Rethinking Alzheimer's disease therapy: are mitochondria the key?

Ankarcrona M, Mangialasche F, Winblad B.

J Alzheimers Dis. 2010;20 Suppl 2:S579-90. doi: 10.3233/JAD-2010-100327.

Effects of cholinesterase inhibitors on visual attention in drivers with Alzheimer disease

Daiello LA, Ott BR, Festa EK, Friedman M, Miller LA, Heindel WC.

J Clin Psychopharmacol. 2010 Jun;30(3):245-51. doi: 10.1097/JCP.0b013e3181da5406.

Bapineuzumab

Kerchner GA, Boxer AL.

Expert Opin Biol Ther. 2010 Jul;10(7):1121-30. doi: 10.1517/14712598.2010.493872.

NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia

Edland SD, Emond JA, Aisen PS, Petersen RC.

Alzheimer Dis Assoc Disord. 2010 Apr-Jun;24(2):159-64. doi: 10.1097/WAD.0b013e3181c9983f.

A single ascending dose study of bapineuzumab in patients with Alzheimer disease

Black RS, Sperling RA, Safirstein B, Motter RN, Pallay A, Nichols A, Grundman M.

Alzheimer Dis Assoc Disord. 2010 Apr-Jun;24(2):198-203. doi: 10.1097/WAD.0b013e3181c53b00.

APP transgenic mouse models and their use in drug discovery to evaluate amyloid- lowering therapeutics

Hussain I.

CNS Neurol Disord Drug Targets. 2010 Aug;9(4):395-402. doi: 10.2174/187152710791556087.

The usefulness and challenges of transgenic mouse models in the study of Alzheimer's disease

Wilcock DM.

CNS Neurol Disord Drug Targets. 2010 Aug;9(4):386-94. doi: 10.2174/187152710791556168.

Retrospect and prospect of active principles from Chinese herbs in the treatment of dementia

Wang Y, Huang LQ, Tang XC, Zhang HY.

Acta Pharmacol Sin. 2010 Jun;31(6):649-64. doi: 10.1038/aps.2010.46.

Tacrine-NO donor and tacrine-ferulic acid hybrid molecules as new anti-Alzheimer agents: hepatotoxicity and influence on the cytochrome P450 system in comparison to tacrine

Lupp A, Appenroth D, Fang L, Decker M, Lehmann J, Fleck C.

Arzneimittelforschung. 2010;60(5):229-37. doi: 10.1055/s-0031-1296278.

Phospholipase A2 and arachidonic acid in Alzheimer's disease

Sanchez-Mejia RO, Mucke L.

Biochim Biophys Acta. 2010 Aug;1801(8):784-90. doi: 10.1016/j.bbalip.2010.05.013. Epub 2010 May 27.

Modulation of mitochondrial calcium as a pharmacological target for Alzheimer's disease

Hung CH, Ho YS, Chang RC.

Ageing Res Rev. 2010 Oct;9(4):447-56. doi: 10.1016/j.arr.2010.05.003. Epub 2010 May 27.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias